Class / Patent application number | Description | Number of patent applications / Date published |
514530000 | Z contains a cyclopentyl or cyclopentene ring | 82 |
20080249166 | Cycloalkyl-Hydroxyl Compounds and Compositions for Cholesterol Management - The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents. | 10-09-2008 |
20080312321 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES - Therapeutic compounds are disclosed herein. | 12-18-2008 |
20080319066 | Jasmonate Derivative Compounds, Pharmaceuticals Compounds and Methods of Use Thereof - The present invention provides novel jasmonate derivative compounds, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for treatment of cancers, especially mammalian cancers. | 12-25-2008 |
20090030076 | PROSTAGLANDIN DERIVATIVES - Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension. | 01-29-2009 |
20090082442 | DEUTERIUM-ENRICHED LUBIPROSTONE - The present application describes deuterium-enriched lubiprostone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-26-2009 |
20090088473 | METHOD FOR SCREENING OF PROSTAGLANDIN COMPOUNDS COMPRISING AN OPTIMAL FORMULATION FOR THE ENHANCEMENT OF HAIR GROWTH AND THE STIMULATION OF FOLLICULAR ANAGEN AND FORMULATIONS RESULTING THEREFROM - A method for developing Prostaglandin F | 04-02-2009 |
20090124688 | Prostaglandin reductase inhibitors - A method of inhibiting 15-keto prostaglandin-Δ | 05-14-2009 |
20090264523 | Method for Prevention of Degradation of Thermally Unstable Medicament - The present invention provides a method for preventing the degradation of a thermally unstable medicament in an eye drop containing the medicament thereby to stabilize the eye drop. By adding an organic amine to an eye drop containing a thermally unstable medicament, the degradation of the medicament in the eye drop can be effectively prevented, and therefore the eye drop can be stably stored. | 10-22-2009 |
20090298936 | METHOD FOR ENERGIZING HUMAN BEINGS - The present invention relates to a method for energizing a human being and to administering an energizing (personal care) composition to human beings wherein said composition contains one or more fragrance materials of group (a) of the present invention. | 12-03-2009 |
20090318549 | COMBINATION TREATMENT OF GLAUCOMA - The methods described herein provide reduction of intraocular pressure by administering a sustained release formulation including latanoprost and a pharmaceutically acceptable vehicle and administering an eye drop adjunctive composition to the eye of a patient. The sustained release formulation can release latanoprost continuously for at least 90 days from a punctum plug delivery system. The eye drop adjunctive composition can also include latanoprost. | 12-24-2009 |
20100016427 | EXTERNAL PREPARATION COMPRISING PROSTAGLANDIN DERIVATIVE - Provided is an external preparation comprising a complex containing: any one of a prostaglandin derivative, a pharmaceutically acceptable salt thereof and a hydrate thereof; and cyclodextrin, the prostaglandin derivative being represented by the following formula (I): | 01-21-2010 |
20100087523 | Rupestonic acid derivatives and use thereof - Rupestonic acid derivatives are rupestonic acid derivative A- or B-type compounds, prepared through a condensation reaction from starting materials, i.e., a monomer compound of rupestonic acid and an aromatic amine or fatty amine or an organic alcohol, i.e., a fatty alcohol or an aromatic alcohol. Rupestonic acid, which is the monomer compound of sesquiterpene isolated from the plant Xinjiang | 04-08-2010 |
20100105771 | AMINO ACID SALTS OF PROSTAGLANDINS - The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them. | 04-29-2010 |
20100120908 | EYE DROP PREPARATION COMPRISING LATANOPROST - Disclosed is an eye drop preparation comprising latanoprost, which is characterized in that the degradation of latanoprost in water can be prevented, the adsorption of latanoprost onto a plastic container can be prevented, and therefore the decrease in the latanoprost content can be prevented satisfactorily. The eye drop preparation comprises an eye drop composition comprising the following components (A)-(B) and packed in a plastic container: (A) latanoprost; and (B) a nonionic surfactant. | 05-13-2010 |
20100130603 | MEDICAMENT FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF DERMATOSIS RESULTING FROM EXCESSIVELY ADVANCED KERATINIZATION - A medicament for prophylactic and/or therapeutic treatment of a dermatosis resulting from excessively advanced keratinization, such as non-hereditary inflammatory keratosis and hereditary congenital keratosis, which comprises a substance selected from the group consisting of a cannabinoid agonist and a vanilloid agonist as an active ingredient. | 05-27-2010 |
20100137432 | OPHTHALMIC COMPOSITION COMPRISING A PROSTAGLANDIN - The present invention relates to a pharmaceutical composition suitable for ophthalmic use comprising one or more prostaglandin derivatives or salts, a stabilizing amount of polyethylene glycol hydroxystearate and pharmaceutically acceptable vehicle. | 06-03-2010 |
20100190853 | TOPICAL APPLICATION OF TRAVOPROST FOR COMBATING HAIR LOSS - Travoprost medicament compositions for non-daily topical application are useful for simulating or inducing the growth and/or decreasing the loss and/or increasing the density and/or reducing the heterogeneity in the diameter of human hair shafts/follicles, e.g., for the treatment of androgenic alopecia, such medicament compositions being at least twice applied over a time interval of greater than 24 hours. | 07-29-2010 |
20100197783 | Radiation Protection Using Single Wall Carbon Nanotube Derivatives - A method of reducing side effects of damage in a human subject exposed to radiation includes administering to the human subject carbon nanotubes in a pharmaceutically acceptable carrier after or prior to exposure to radiation. A composition for reducing radical damage includes a carbon nanotube which is functionalized (1) for substantial water solubility and (2) with a radical trapping agent appended to the carbon nanotube forming a radical scavenger-carbon nanotube conjugate. | 08-05-2010 |
20100204320 | PHARMACEUTICALS FOR XEROSIS - A method for preventing or treating xerosis by applying a prostaglandin D receptor selective agonist to a mammal. | 08-12-2010 |
20100210720 | PRESERVATIVE-FREE PROSTAGLANDIN-BASED OPHTHALMIC SOLUTION - The present invention provides an ophthalmic solution without an antimicrobial preservative. The solution includes as an active substance at least one prostaglandin and as a solubilizing agent, a surfactant, where the solubilizing agent is polyoxyl-15-hydroxystearate. | 08-19-2010 |
20100216877 | Storage Stable Prostaglandin Product - A prostaglandin composition comprising prostaglandin and a low-density polyethylene container are disclosed. The prostaglandin compositions are stable in polyethylene containers over longer period of time. | 08-26-2010 |
20100249229 | BICYCLIC gamma-AMINO ACID DERIVATIVE - It is intended to provide a bicyclic γ-amino acid derivative having excellent activity as an α | 09-30-2010 |
20100267826 | Treatment of ischemic episodes and cerebroprotection through Prostaglandin E2 (PGE2) EP2 and/or EP4 receptor agonists - The present invention provides compositions and methods for treating an ischemic episode using PGE | 10-21-2010 |
20100331407 | Clear ophthalmic solution comprising latanoprost as active ingredient - A clear ophthalmic solution containing latanoprost having a concentration of 0.005% (W/V), 0.003 to 0.01% (W/V) benzalkonium chloride and at least one agent selected from the group consisting of glycerin, polyethylene glycol, propylene glycol and trehalose, wherein the agent is in a concentration to make the solution isotonic. A method of preventing white turbidity in an ophthalmic solution containing latanoprost having a concentration of 0.005% (W/V) and 0.003 to 0.01% (W/V) benzalkonium chloride, the method involving adding to the solution at least one agent selected from the group consisting of glycerin, polyethylene glycol, propylene glycol and trehalose, wherein the agent is in a concentration to make the solution isotonic. | 12-30-2010 |
20110065790 | LATANOPROST-CONTAINING AQUEOUS PHARMACEUTICAL COMPOSITION - The invention provides a latanoprost-containing aqueous pharmaceutical composition filled in a filter-equipped container, with the adsorption of latanoprost by the filter being prevented. In the latanoprost-containing aqueous pharmaceutical composition filled in the filter-equipped container, a nonionic surfactant is contained in the composition and the filter is made from at least one material selected from the group consisting of polyether sulfone, polyvinylidene fluoride, polycarbonate, and polytetrafluoroethylene. | 03-17-2011 |
20110098354 | METHOD OF PREPARING A LATANOPROST OPHTHALMIC SOLUTION AND THE RESULTING SOLUTION - A method of solubilizing an analog active agent of the prostaglandin F2α, such as latanoprost, is described and a method of preparing an ophthalmic solution of the solubilized latanoprost for the treatment of distinct ocular ailments. This invention also refers to an ophthalmic aqueous solution resulting from the aforementioned method, which is characterized by its chemical stability at room temperature, its safety, and innocuousness and efficiency in the treatment of the patient. The new ophthalmic aqueous solution is distinguished because its pharmaceutical value is found in the handling of a vehicle of easy access that not only permits the solubility of latanoprost, but also promotes its chemical stability and, a greater tolerance of the patient with its ophthalmic application for the treatment of the patient's ailment. | 04-28-2011 |
20110098355 | METHOD OF PREPARING A LATANOPROST OPHTHALMIC SOLUTION AND RESULTING SOLUTION - A method of solubilizing an analog active agent of the prostaglandin F2α, such as latanoprost, is described and a method of preparing an ophthalmic solution of the solubilized latanoprost for the treatment of distinct ocular ailments. This invention also refers to an ophthalmic aqueous solution resulting from the aforementioned method, which is characterized by its chemical stability at room temperature, its safety, and innocuousness and efficiency in the treatment of the patient. The new ophthalmic aqueous solution is distinguished because its pharmaceutical value is found in the handling of a vehicle of easy access that not only permits the solubility of latanoprost, but also promotes its chemical stability and a greater tolerance of the patient with its ophthalmic application for the treatment of the patient's ailment. | 04-28-2011 |
20110105605 | METHOD OF PREPARING A LATANOPROST OPHTHALMIC SOLUTION AND THE RESULTING SOLUTION - A method of solubilizing an analog active agent of the prostaglandin F2α, such as latanoprost, is described and a method of preparing an ophthalmic solution of the solubilized latanoprost for the treatment of distinct ocular ailments. This invention also refers to an ophthalmic aqueous solution resulting from the aforementioned method, which is characterized by its chemical stability at room temperature, its safety, and innocuousness and efficiency in the treatment of the patient. The new ophthalmic aqueous solution is distinguished because its pharmaceutical value is found in the handling of a vehicle of easy access that not only permits the solubility of latanoprost, but also promotes its chemical stability and a greater tolerance of the patient with its ophthalmic application for the treatment of the patient's ailment. | 05-05-2011 |
20110118348 | Methods of stabilizing latanoprost in an aqueous solution - A method of stabilizing latanoprost in an ophthalmic solution containing 0.005% (W/V) of latanoprost to be stored to be stored at room temperature (i) by adding 0.1 to 2% (W/V) of ε-aminocaproic acid to the solution or (ii) by adding 0.1 to 2% (W/V) of ε-aminocaproic acid and adjusting the pH of the solution to 5.0 to 6.25. | 05-19-2011 |
20110118349 | USE OF PROSTAGLANDINS F2ALPHA AND ANALOGUES FOR THE HEALING OF CORNEAL AND CONJUNCTIVAL LESIONS - A composition for use in treating corneal and conjunctival lesions, includes a prostaglandin F2alpha or analogue, in a therapeutic amount, the composition being in a form suitable for topical application on the ocular surface and is free of deleterious preservative. A method for treating surface ocular conditions in a patient in need thereof, includes administering an effective amount of the composition. | 05-19-2011 |
20110136904 | PROSTAGLANDIN DERIVATIVES - Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension. | 06-09-2011 |
20110275711 | METHOD FOR TREATING MACULAR EDEMA - Provided is a method for treating macular edema in a mammalian subject, comprising administering an effective amount of a fatty acid derivative to the subject in need thereof. The method of the present invention can effectively treat macular edema in a non-invasive manner. In one embodiment of the present invention, the fatty acid derivative is isopropyl unoprostone. | 11-10-2011 |
20110294880 | PHARMACEUTICAL COMPOSITION CONTAINING PROSTAGLANDIN - An object of the present invention is to provide a stable aqueous pharmaceutical composition which suppresses degradation of prostaglandin F | 12-01-2011 |
20110313038 | CATIONIC OIL-IN-WATER EMULSIONS CONTAINING PROSTAGLANDINS AND USES THEREOF - A colloidal cationic oil-in-water emulsion includes: —a prostaglandin, —an oil having a iodine value ≦2, —one or more surfactants including at least one quaternary ammonium compound, —water, wherein the prostaglandin/total sum of surfactants mass ratio is included between 0.5 and 5. The use of the cationic oil-in-water emulsions for enhancing the stability of the prostaglandins, for the treatment of ocular hypertension and/or glaucoma, for promoting growth of eyelashes and/or for treating eyelash hypotrichosis is also described. | 12-22-2011 |
20110319487 | POLYMERIC DELIVERY SYSTEM FOR A NONVISCOUS PROSTAGLANDIN-BASED SOLUTION WITHOUT PRESERVATIVES - This invention concerns an ophthalmic solution including:
| 12-29-2011 |
20110319488 | ANIONIC OIL-IN-WATER EMULSIONS CONTAINING PROSTAGLANDINS AND USES THEREOF - A colloidal anionic oil-in-water emulsion includes a prostaglandin, an oil having a iodine value ≦2, a surfactant and water, provided the anionic oil-in-water emulsion does not contain polyvinyl alcohol. The use of the anionic oil-in-water emulsions for enhancing the stability of the prostaglandins, for the treatment of ocular hypertension and/or glaucoma, for promoting growth of eyelashes and/or for treating eyelash hypotrichosis is also described. | 12-29-2011 |
20120029073 | PHARMACEUTICAL COMPOSITIONS HAVING DESIRABLE BIOAVAILABILITY - The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as travoprost and the surfactant is a vegetable oil such as castor oil. | 02-02-2012 |
20120046359 | Bed bug control and repellency - Control or repellency of bed bugs by bringing the bed bugs into contact with a bed bug control formulation containing at least one compound selected from the group consisting of certain alkyl ketones and cyclic ketones wherein the total number of carbon atoms in the alkyl ketones and cyclic ketones is from 10 to 16 carbon atoms and method for achieving such control or repellency. | 02-23-2012 |
20120065258 | STABLE PROSTAGLANDIN-CONTAINING COMPOSITIONS - A pharmaceutical composition containing a prostaglandin and an alkanoic acid ester of a polyethoxylated sorbitol in an amount effective to enhance the chemical stability of the prostaglandin, and the use thereof for treating ophthalmic conditions. Also disclosed are methods for enhancing the chemical stability of a prostaglandin-containing composition by using an alkanoic acid ester of a polyethoxylated sorbitol. | 03-15-2012 |
20120083529 | USE OF JASMONATE ESTER DERIVATIVES FOR TREATING BENIGN HYPERPROLIFERATIVE SKIN DISORDERS - The present invention relates to methods of treating benign hyperproliferative diseases of the epidermis by administering a composition comprising at least one jasmonate ester derivative, preferably methyl jasmonate. In particular, the present invention provides jasmonate ester derivatives as potent compounds useful for the treatment of disorders such as actinic keratoses with reduced side effects. | 04-05-2012 |
20120122976 | PHOSPHATE-FREE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GLAUCOMA - The invention relates to a phosphate-free pharmaceutical composition which comprises at least one FP prostanoid receptor agonist and/or at least one prostamide receptor agonist and also citrate salts and/or citric acid. | 05-17-2012 |
20120184615 | STABILISED PROSTAGLANDIN COMPOSITION - A pharmaceutical delivery device, such as a suppository or pessary, comprises a synthetic prostaglandin PGE | 07-19-2012 |
20120225938 | METHOD FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS - The present invention provides a method for treating a central nervous system disorder in a mammalian subject, which comprises administering an effective amount of a 11-deoxy-prostaglandin compound to a subject in need thereof. The invention also provide novel 11-deoxy-prostaglandin compound. | 09-06-2012 |
20120225939 | Use of Prostaglandins F2Alpha and Analogues for the Healing of Corneal and Conjunctival Lesions - The invention relates to a composition for use in treating corneal and conjunctival lesions, wherein the composition comprises a prostaglandin F2alpha or analogue, in a therapeutic amount, said composition being in a form suitable for topical application on the ocular surface and is free of deleterious preservative; the invention also relates to a method for treating surface ocular conditions in a patient in need thereof, comprising administering a composition of the invention. | 09-06-2012 |
20120232139 | COMPOSITION FOR OCULAR TOPICAL ADMINISTRATION TREATMENT OCULAR HYPERTENSION AND GLAUCOMA - The present invention provides a composition for ocular topical administration for treating ocular hypertension and glaucoma, comprising latanoprost as an active ingredient, and (a) a polyol and/or sugar alcohol, (b) a nonionic surface active agent, and (c) an edetic acid compound. The composition of the present invention comprises lower amount of preservatives such as benzalkonium chloride comparative to the conventional product and therefore, can reduce incidence of the adverse side effects caused by the preservatives. In addition, the composition of the present invention can be stored stably at room temperatures for a long term. | 09-13-2012 |
20120245227 | PHARMACEUTICAL COMPOSITIONS HAVING DESIRABLE BIOAVAILABILITY - The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as travoprost and the surfactant is a vegetable oil such as castor oil. | 09-27-2012 |
20120259008 | METHOD FOR TREATING ASTHENOPIA - The present invention relates to a method for treating asthenopia, accommodative dysfunction or ocular pain comprising an administration of a specific prostaglandin compound to a mammalian subject. The present invention also relates to a composition for treating asthenopia, accommodative dysfunction or ocular pain comprising a specific prostaglandin compound. | 10-11-2012 |
20120270941 | TOPICAL APPLICATION OF TRAVOPROST FOR COMBATING HAIR LOSS - Travoprost medicament compositions for non-daily topical application are useful for simulating or inducing the growth and/or decreasing the loss and/or increasing the density and/or reducing the heterogeneity in the diameter of human hair shafts/follicles, e.g., for the treatment of androgenic alopecia, such medicament compositions being at least twice applied over a time interval of greater than 24 hours. | 10-25-2012 |
20120302635 | Water-Swellable Polymers - A water-swellable linear polyurethane polymer is formed by reacting a polyethylene oxide (e.g. PEG 4000 to 35,000), a difunctional compound (e.g. a diamine or diol such as 1,10-decanediol) with a diisocyanate. The ratio of the three components is generally in the range 0.1-1.5 to 1 to 1.1-2.5. The polyurethane is water-swellable in the range 300 to 1700% and soluble in certain organic solvents such as dichloromethane. It can be loaded with pharmaceutically active agents, particularly of high molecular weight, to produce controlled release compositions, such as pessaries etc. | 11-29-2012 |
20120322871 | POLYMERIC DELIVERY SYSTEM FOR A NONVISCOUS PROSTAGLANDIN-BASED SOLUTION WITHOUT PRESERVATIVES - This invention concerns an ophthalmic solution including:
| 12-20-2012 |
20130005805 | ESTERS FOR TREATMENT OF OCULAR INFLAMMATORY CONDITIONS - The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a monohydric alcohol or an amide wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens. | 01-03-2013 |
20130046014 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF INCREASED INTRAOCULAR PRESSURE - The invention provides novel pharmaceutical compositions for the treatment of increased intraocular pressure based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble prostaglandin analogues. The compositions can be administered topically into the eye. The invention further provides kits comprising such compositions. | 02-21-2013 |
20130053440 | Self-Preserved Aqueous Pharmaceutical Compositions - The present invention is directed to the provision of multi-dose, self-preserved ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP), without requiring the presence of conventional anti-microbial preservative agents, such as benzalkonium chloride. The compositions are effectively preserved by a balanced ionic buffer system containing zinc ions at a concentration of 0.04 to 0.9 mM, preferably 0.04 to 0.4 mM. One aspect of the balanced buffer system is limitation of the amount of buffering anions present to a concentration of 15 mM or less, preferably 5 mM or less. In a preferred embodiment, the compositions also contain borate or, most preferably, one or more borate/polyol complexes. The use of propylene glycol as the polyol in such complexes is strongly preferred. Limiting the amount of divalent metals other than zinc and the amount of ionized salts present has also been determined to be important to maximize the antimicrobial activity of the balanced buffer systems. | 02-28-2013 |
20130158114 | Calcilytic Compounds - Novel calcilytic compounds and methods of using them are provided. | 06-20-2013 |
20130178524 | PROSTAGLANDIN-CONTAINING PRODUCT - A prostaglandin-containing product including an aqueous liquid preparation containing 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostaglandin F2α, or an alkyl ester or salt thereof, and a resin container containing said aqueous liquid preparation, the resin container being formed from a polymer alloy of polyethylene terephthalate and polyarylate, wherein a component ratio of polyethylene terephthalate/polyarylate is 1/2 to 2/1, thereby inhibiting a decrease of the content of the 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostaglandin F2α or an alkyl ester or salt thereof, in the aqueous liquid preparation. | 07-11-2013 |
20130178525 | METHODS AND COMPOSITIONS FOR REDUCING BODY FAT AND ADIPOCYTES - Provided are methods of reducing body fat in a subject, comprising locally (e.g., topically) administering one or more compounds of the Formula (I) and/or (V): | 07-11-2013 |
20130197081 | INTRAVAGINAL ADMINISTRATION OF MISOPROSTOL - A method for decreasing likelihood of cesarean section delivery in a female in need thereof, comprises administering, intravaginally, to said female, misoprostol. | 08-01-2013 |
20130210912 | Ophthalmic Pharmaceutical Compositions and Methods of Making and Using Same - A stable ophthalmic pharmaceutical composition for relief, treatment, control, alleviation, or prevention of a pathological ocular condition of the eye comprises: (a) a first polymer, a viscosity of which changes with a change in a concentration of an electrolyte, such as a salt, when added to said first polymer; (b) a second polymer that is different from the first polymer and can modify the viscosity of the first polymer; and (c) an oil. In some embodiments, the composition further comprises a non-ionic surfactant. The composition can form a stable oil-in-water emulsion on storage, but separate into an oil phase and a water phase when applied in the eye. The emulsion can comprises an ophthalmic active pharmaceutical ingredient dissolved in the oil or water phase. The emulsion can provide enhanced stability to said active pharmaceutical ingredient. | 08-15-2013 |
20130217767 | Cosmetic Composition - The present invention concerns a cosmetic composition comprising the following fluorinated analog of prostaglandin F2α: The cosmetic composition may further comprise a complexing agent and/or a humectant. The present invention further relates to a cosmetic kit, comprising the cosmetic composition and an applicator for application thereof. | 08-22-2013 |
20130261179 | Stabilised Prostaglandin Composition - A pharmaceutical delivery device, such as a suppository or pessary, comprises a synthetic prostaglandin PGE | 10-03-2013 |
20130267591 | NOVEL OPHTHALMIC COMPOSITIONS - An ophthalmic solution comprising therapeutically effective amount of a prostaglandin or its analog and water soluble excipient(s) dissolved in a pharmaceutically acceptable vehicle, wherein the solution is free of a surfactant. | 10-10-2013 |
20130281529 | EYE DROP PREPARATION COMPRISING LATANOPROST - It is intended to provide an eye drop preparation capable of preventing not only degradation of latanoprost in water but also adsorption of latanoprost onto a plastic container so that a decrease in latanoprost content thereof is satisfactorily prevented. The eye drop preparation contains an ophthalmic solution composition containing components (A) and (B) and packed in a plastic container: (A) latanoprost; and (B) a nonionic surfactant. | 10-24-2013 |
20140031423 | AMINO ACID SALTS OF PROSTAGLANDINS - The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them. | 01-30-2014 |
20140057980 | CALCILYTIC COMPOUNDS - Novel calcilytic compounds and methods of using them are provided. | 02-27-2014 |
20140107195 | WATER-SWELLABLE POLYMERS - A water-swellable linear polyurethane polymer is formed by reacting a polyethylene oxide (e.g. PEG 4000 to 35,000), a difunctional compound (e.g. a diamine or diol such as 1,10-decanediol) with a diisocyanate. The ratio of the three components is generally in the range 0.1-1.5 to 1 to 1.1-2.5. The polyurethane is water-swellable in the range 300 to 1700% and soluble in certain organic solvents such as dichloromethane. It can be loaded with pharmaceutically active agents, particularly of high molecular weight, to produce controlled release compositions, such as pessaries etc. | 04-17-2014 |
20140163098 | COMPOSITIONS AND METHODS FOR REDUCING BODY FAT - The present invention relates to compositions, such as bimatoprost, latanoprost and travoprost, and methods to reduce fat in the body of an individual, for example, by topical administration, injection, and/or implantation of such compositions. | 06-12-2014 |
20140213646 | Sustained Release Formulations for the Treatment of Intraocular Pressure or Glaucoma - The present embodiments provide for methods of treating elevated intraocular pressure or glaucoma using a sustained release medicament consisting of prostaglandin in benzyl benzoate that is injected intraocularly no more frequently than once every two months. | 07-31-2014 |
20140243409 | PHARMACEUTICAL COMPOSITIONS HAVING DESIRABLE BIOAVAILABILITY - The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as travoprost and the surfactant is a vegetable oil such as castor oil. | 08-28-2014 |
20140350103 | SUSTAINED RELEASE DELIVERY OF ACTIVE AGENTS TO TREAT GLAUCOMA AND OCULAR HYPERTENSION - A method of decreasing intraocular pressure (IOP) in an eye of a patient in need thereof includes implanting a first lacrimal implant through a firsts punctum and into a first lacrimal canaliculus of the eye of the patient. The method may further comprise implanting a second lacrimal implant through a second punctum and into a second lacrimal canaliculus of the eye of the patient, and releasing, on a sustained basis a therapeutically effective amount of an intraocular pressure-reducing therapeutic agent. | 11-27-2014 |
20140350104 | METHODS AND COMPOSITIONS FOR REDUCING BODY FAT AND ADIPOCYTES - Provided are methods of reducing body fat in a subject, comprising locally (e.g., topically) administering one or more compounds of the Formula (I) and/or (V) or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, polymorph, tautomer, isotopically enriched derivative, or prodrug thereof, wherein X is —OR | 11-27-2014 |
20140364494 | PROCESSES FOR MAKING CYCLIC LIPID IMPLANTS FOR INTRAOCULAR USE - Biocompatible implants comprising a cyclic lipid therapeutic agent are made using a low temperature melt extrusion process. The implants are suitable for intraocular use to treat an ocular condition. | 12-11-2014 |
20140371308 | HYPOTENSIVE LIPID-CONTAINING BIODEGRADABLE INTRAOCULAR IMPLANTS AND RELATED METHODS - Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma. | 12-18-2014 |
20140371309 | OPHTHALMIC SOLUTION - The present invention relates to an ophthalmic solution comprising a prostaglandin compound and viscosity-increasing compound. The ophthalmic solution of the invention is excellent in stability and can provide long lasting and increased effect when administrated topically to the eyes of a patient. | 12-18-2014 |
20150099805 | Hypotensive lipid-containing biodegradable intraocular implants and related methods - Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma. | 04-09-2015 |
20150105462 | COMPOSITIONS AND METHODS FOR TOPICAL DELIVERY OF PROSTAGLANDINS TO SUBCUTANEOUS FAT - Described herein are compositions comprising a prostaglandin FP receptor agonist (PFPRA) compound and a fatty acid ester (e.g., isopropyl myristate), optionally comprising an ointment base such as a hydrocarbon base (e.g., petroleum jelly) and/or an organic alcohol (e.g., propylene glycol), that, when topically applied to the skin, locally delivers a therapeutically effective amount of the PFPRA compound to subcutaneous fat under the skin, and methods of preparation. The therapeutic effect is, for example, reduction of the subcutaneous fat under the skin. Further provided are methods of reducing body fat in a subject comprising topically administering the composition to the subject. | 04-16-2015 |
20150133546 | SUSTAINED RELEASE DELIVERY OF ONE OR MORE AGENTS - The lacrimal implant delivery systems and methods described herein provide for controlled release of a therapeutic agent for the treatment of disease, including the treatment of glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti-glaucoma agents. Treatment of disease, including glaucoma, ocular hypertension, or elevated intraocular pressure with latanoprost or other anti-glaucoma agent in conjunction with penetration enhancer, such as benzalkonium chloride, and/or artificial tears is also provided. Also provided are implants containing a drug core emplacable in a punctum adjacent to an eye of a patient for controlled release of a therapeutic agent such as latanoprost for the treatment of glaucoma, the drug core containing a polymer such as cross-linked silicone, a therapeutic agent, and an excipient, wherein the excipient can increase the rate of release of the agent from the drug core, or can increase the drug loading in the core without loss of desirable homogeneity of the agent within the core, or can improve retention of the agent in the eye or in tear fluid, or can increase corneal penetration of the agent into the eye. | 05-14-2015 |
20150359801 | COMPOSITIONS AND METHODS FOR REDUCING BODY FAT - The present invention relates to compositions, such as bimatoprost, latanoprost and travoprost, and methods to reduce fat in the body of an individual, for example, by topical administration, injection, and/or implantation of such compositions. | 12-17-2015 |
20160008310 | MISOPROSTOL DISPERSIBLE TABLET | 01-14-2016 |
20160051562 | METHODS AND COMPOSITIONS FOR REDUCING BODY FAT AND ADIPOCYTES - Provided are methods of reducing body fat in a subject, comprising locally (e.g., topically) administering one or more compounds of the Formula (I) and/or (V): | 02-25-2016 |
20160067263 | METHODS AND COMPOSITIONS FOR TOPICAL DELIVERY OF PROSTAGLANDINS TO SUBCUTANEOUS FAT - Described herein are compositions comprising a prostaglandin FP receptor agonist (PFPRA) compound and a fatty acid, e.g., oleic acid, that, when topically applied to the skin, locally delivers a therapeutically effective amount of the PFPRA compound or active metabolite thereof to subcutaneous fat under the skin. The therapeutic effect is, for example, reduction of the subcutaneous fat under the skin. Further provided are methods of reducing body fat in a subject comprising topically administering the composition to the subject. The present invention also provides kits comprising the composition and instructions for use. | 03-10-2016 |
20160113942 | COMPOSITIONS COMPRISING A PROSTAGLANDIN FOR TREATING NEUROPSYCHIATRIC CONDITIONS - The present invention relates to methods and compositions for the treatment of neuropsychiatric conditions (e.g., bipolar disorder) by administration of prostaglandin or prostaglandin derivatives (e.g., latanoprost) to a subject (e.g., a human). | 04-28-2016 |
20160151386 | SUSTAINED RELEASE FORMULATIONS FOR THE TREATMENT OF INTRAOCULAR PRESSURE OR GLAUCOMA | 06-02-2016 |